Immunovant, Inc. IMVT Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.
The official record: Immunovant, Inc.’s 10-Q, filed February 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value?
- Immunovant, Inc. (IMVT) reported share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value of $117.2M in Q4 2025.
- How has Immunovant, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value changed year-over-year?
- Immunovant, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value decreased by 34.5% year-over-year, from $178.9M to $117.2M.
- What is the long-term trend for Immunovant, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value?
- Over 4 years (2021 to 2025), Immunovant, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value has grown at a 36.1% compound annual growth rate (CAGR), from $25.96M to $88.96M.